21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
19:33 , May 17, 2019 |  BC Extra  |  Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
22:34 , May 14, 2019 |  BC Extra  |  Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data  Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in...
23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
11:10 , May 8, 2019 |  BC Extra  |  Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
22:52 , May 3, 2019 |  BC Extra  |  Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
22:44 , Apr 25, 2019 |  BC Extra  |  Clinical News

Gilead looks towards NASH combo data after selonsertib fails in second Phase III

Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
17:13 , Apr 19, 2019 |  BC Week In Review  |  Company News

ImmunoForge gets rights to PB1023 from PhaseBio

PhaseBio granted ImmunoForge exclusive, worldwide rights to develop and commercialize PB1023 for all indications except diabetes, obesity and non-alcoholic steatohepatitis (NASH). ImmunoForge Co. Ltd. (Seoul, South Korea) will develop the compound for serious sarcopenia-related diseases....
19:57 , Apr 12, 2019 |  BC Extra  |  Company News

Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in...